Endeavor BioMedicines, a clinical-stage biotech company, has announced promising phase 2a trial results for its lead investigational candidate, ENV-101.

Closed Loop Medicine, a techbio company specializing in personalized drug-plus-software therapies, and Pharmanovia, a global pharmaceutical firm known for rejuvenating established medicines, have ...

Proteins present in the blood may be able to predict a person's risk of developing cancer more than seven years before they are diagnosed with the disease, according to new research.

Alchemab Therapeutics, an antibody discovery firm known for identifying natural antibodies in disease-resistant individuals, has published a peer-reviewed article titled "Predictability of B cell ...

Key competitors include Boehringer Ingelheim’s cathepsin C inhibitor BI-1291583, Regeneron’s anti-IL-33 monoclonal antibody itepekimab, Chiesi’s human neutrophil elastase inhibitor CHF-6333, Armata ...

Oxford BioDynamics (OBD) and King’s College London (KCL) have partnered to use OBD’s EpiSwitch technology to identify patients at risk of rheumatoid arthritis (RA) who can benefit from abatacept ...

Anti-obesity jabs could reduce the risk of heart attacks, strokes or heart failure in obese people irrespective of the amount of weight they lose while using the medication, according to a new study.

Before the industry is set to arrive in San Diego for Bio International 2024, we spoke with Dr. Harald Oberegger, global head business development at Novartis Contract Manufacturing. At the event, the ...

Regeneron Pharmaceuticals’ gene therapy for otoferlin-related hearing loss, a genetic cause of deafness, has restored hearing to normal levels in one deaf child within just 24 weeks.

Hazel Jones is the interim CEO and chief operations officer at Enhanc3D Genomics. We sat down with her to discuss her leap of faith into 3D genomics, and how she is scaling the business and driving ...

Cambridge-based drug discovery firm Cresset Group has bolstered its global footprint with the establishment of a new Indian headquarters in Bangalore.

Abzena, an end-to-end CDMO for biologics and bioconjugates, will be presenting its latest AbZelect and AbZelectPRO cell line development (CLD) platforms and more at BIO 2024.